Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | HTR2B | P41595 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721007 | 0.82 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| SCHEMBL8550985 | 0.80 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| SCHEMBL644545 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| SCHEMBL6028221 | 0.78 | CHRNB2 (0.41) | SLC6A2SLC6A4SLC6A3HTR2CHTR2B | |
| SCHEMBL28025658 | 0.78 | MBTD1 (0.36) | SLC18A3 | |
| Bromide SCHEMBL27797303 | 0.77 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| Hydrochloric Acid SCHEMBL5793498 | 0.77 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| SCHEMBL15974677 | 0.76 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| SCHEMBL8780409 | 0.76 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C | |
| SCHEMBL5506036 | 0.74 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3ADRB1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A2 13/4885SLC6A4 26/4885SLC6A3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.